Table 3.
Reactivity of SEREX-Defined Antigens Screened with Sera from Healthy Donors and Patients with Prostate Cancer
| Designation | Identity | Serological reactivity | |
| Control | Pca | ||
| Pr1 | Trans-Golgi P230 autoantigen | 5-May | 9-Sep |
| Pr2 | aarF domain containing kinase 4 | 0/14 | 4/13 |
| Pr3 | Unknown | 2/14 | 6/7 |
| Pr4 | SATB2 | 1/14 | 2/13 |
| Pr5 | Mitochondrical protein | 0/4 | 0/9 |
| Pr6 | Unknown | 3/13 | 12/14 |
| Pr7 | Ribosomal protein S8 | 6/13 | 13/14 |
| Pr8 | Ribosomal protein L27a | 0/13 | 1/14 |
| Pr9 | Hypothetical protein LOC116228 | 1/10 | 1/7 |
| Pr10 | Similar to AB25 | 2/13 | 6/14 |
| Pr11 | Unknown | 0/7 | 0/6 |
| Pr12 | DNA-binding protein (HRC1) | 0/13 | 0/8 |
| Pr13 | A alternatively spliced isoform of HRC1 | 0/13 | 1/8 |
| Pr14 | Geminin, DNA replication inhibitor | 1/13 | 1/8 |
| Pr15 | Calcium binding protein (ALG-2) | 1/17 | 4/13 |
| Pr16 | Metastasis-associated1 (MTA1) mRNA | 0/13 | 2/13 |
| Pr17 | NEDD8 ultimate buster-1 | 1/17 | 1/13 |
| Pr18 | Surfeit 6 | 4/13 | 3/8 |
| Pr19 | Phospholipase C-gamma mRNA | 0/13 | 0/8 |
| Pr20 | Scaffold attachment factor A | 0/13 | 0/8 |
| Pr21 | Upstream transcription factor 2, c-fos interacting | 0/13 | 0/8 |
| Pr22 | Ubiquitin specific protease 8 | 3/17 | 7/13 |
| Pr23 | Vesicle docking protein p115 | 0/13 | 0/8 |
| Pr24 | Proteasome subunit HSPC | 6/17 | 10/13 |
| Pr25 | fatty-acid-Coenzyme A ligase, long-chain 5 | 4/17 | 8/13 |
| Pr26 | F1F0-type ATP synthase subunit d mRNA | 0/13 | 0/8 |
| Pr27 | glutamyl-prolyl-tRNA synthetase | 5/17 | 10/13 |
| Pr28 | Ribosimal protein L10 | 2/6 | 5/10 |
| Pr29 | Ribosomal protein S14 | 2/5 | 5/10 |
| Pr30 | Ribosomal protein L18a | 3/5 | 4/10 |
| Pr31 | Ribosomal protein S10 | 0/4 | 5/10 |
| Pr32 | Ribosomal protein L32 | 0/4 | 0/10 |
| Pr35 | Tankyrase | 2/4 | 4/10 |
| Pr41 | Cell death-regulatory protein GRIM19 | 0/6 | 5/12 |
| Pr52 | Unknown | 2/11 | 13-Nov |